January 6, 2014

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2014 ACS

Patent Number: WO 2013177349
Title: Preparation of quinazolinediones as tankyrase inhibitors for the treatment of cancer
Inventor(s): Keenan, Richard M.; Miller, Aaron Bayne; Qin, Donghui
Patent Assignee(s): GlaxoSmithKline LLC, USA
Source: PCT Int. Appl., 81pp. CODEN: PIXXD2
Language: English

Abstract:
The invention relates to quinazolinediones of formula I and their prepn., useful as modulators, notably inhibitors, of tankyrases (TNKS1 and TNKS2) in the treatment of cancer, fibrosis, and other hyperproliferative diseases.  Compds. of formula I, in which R1, R2, and R3 are independently H, halo, C1-4 alkyl, and C1-4 alkoxy, provided that at least one of R1, R2, and R3 is not H; R4 is H and Me; or pharmaceutically acceptable salts thereof, are claimed.  Example compd. II was prepd. by a multistep process (procedure given).  Invention compds. were evaluated for the tankyrase inhibitory activity.  From the assay, it was detd. that II exhibited pIC50 values of 8.1 (TNKS1) and 7.1 (TNKS2).

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention.

 View the full-text here.

Recent News

    January 11, 2016 | Get the Latest Release of STN
    Express, Version 8.6!

    December 23, 2015 | Multi-Year Agreement for
    SciFinder with PatentPak Gives Israeli Academic
    Researchers Competitive Edge

    October 28, 2015 | CAS and Influential Research
    Leaders in Japan Share Common Business
    Challenges in Driving Economic Development
    through Scientific Research
 
                                                                    More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org